Tumor-Type–Specific Tumor Mutational Burden Cutoffs for Improved Immune Checkpoint Inhibitor Outcome Prediction: Large-Scale Analysis with Real-World Targeted Next-Generation Sequencing Data
Cancer Research and Treatment · 2026
DOI: 10.4143/crt.2025.860 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2026. Verfasst von Ha Ra Jun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Science, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, High-Throughput Nucleotide Sequencing, Mutation, Biomarkers, Tumor. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: NCIRD CDC HHS, Asan Institute for Life Sciences, Asan Medical Center, NGeneBio.
Abstract (Originalsprache)
Purpose
Tumor mutational burden (TMB) is a potential biomarker for predicting response to immune checkpoint inhibitors (ICIs). However, its clinical utility is limited by methodological inconsistencies. This study aimed to evaluate the predictive value of TMB for ICI outcomes using next-generation sequencing (NGS) data. Materials and Methods We retrospectively analyzed 9,459 patients with cancer who underwent tumor-only targeted NGS. TMB-high (TMB-H) cutoffs were defined using an interquartile range (IQR)–based method and validated by comparing the overall survival (OS) and progression-free survival (PFS) in ICI-treated cohorts against both The Cancer Genome Atlas whole-exome sequencing–derived TMB and the universal 10 mutations per megabase (mut/Mb) cutoff. We also examined programmed cell death-ligand 1 (PD-L1) expression and subclonality to address response heterogeneity.
Results
IQR-based TMB-H was significantly associated with longer PFS in the ICI-treated cohort (hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.73 to 0.98; p=0.022), NGS before ICI subgroup (HR, 0.86; p=0.049), and pre-ICI subgroup (HR, 0.80; p=0.026). In contrast, the universal 10 mut/Mb cutoff showed no statistical significance. Subgroup analysis revealed significant PFS benefit in bladder (p=0.014), bowel (p=0.013), and uterine cancers (p=0.006). In lung cancer, patients with both TMB-H and very high PD-L1 expression (≥ 90%) had the longest PFS (HR, 0.64; 95% CI, 0.44 to 0.93; p=0.021). Among the TMB-H samples, high subclonality was associated with worse OS in non-hypermutated cases (p=0.032).
Conclusion
Real-world TMB cutoffs derived from distribution-based methods offer improved predictive value for ICI outcomes. Integration of the PD-L1 expression and subclonality status further refines the predictive utility of TMB, improving precision in ICI treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Science, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Asan Center for Cancer Genome Discovery, Asan Institute for Life Science, Asan Medical Center, Seoul, Korea.
- Software Division, NGeneBio, Seoul, Korea.
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. smchun@amc.seoul.kr.
Förderung
- NCIRD CDC HHS
- Asan Institute for Life Sciences, Asan Medical Center
- NGeneBio
Zitieren
APA
Jun, H. R., Lee, J. Y., Lee, C., & Chun, S. M. (2026). Tumor-Type–Specific Tumor Mutational Burden Cutoffs for Improved Immune Checkpoint Inhibitor Outcome Prediction: Large-Scale Analysis with Real-World Targeted Next-Generation Sequencing Data. Cancer Research and Treatment. https://doi.org/10.4143/crt.2025.860
Vancouver
Jun HR, Lee JY, Lee C, Chun SM. Tumor-Type–Specific Tumor Mutational Burden Cutoffs for Improved Immune Checkpoint Inhibitor Outcome Prediction: Large-Scale Analysis with Real-World Targeted Next-Generation Sequencing Data. Cancer Research and Treatment. 2026. doi:10.4143/crt.2025.860
BibTeX
@article{Jun2026,
author = {Jun, Ha Ra and Lee, Ji-Young and Lee, Changseon and Chun, Sung-Min},
title = {Tumor-Type–Specific Tumor Mutational Burden Cutoffs for Improved Immune Checkpoint Inhibitor Outcome Prediction: Large-Scale Analysis with Real-World Targeted Next-Generation Sequencing Data},
journal = {Cancer Research and Treatment},
year = {2026},
doi = {10.4143/crt.2025.860}
}
EUVIMED